MedPath
HSA Approval

SUGAMMADEX-TEVA SOLUTION FOR INJECTION 100MG/ML

SIN16962P

SUGAMMADEX-TEVA SOLUTION FOR INJECTION 100MG/ML

SUGAMMADEX-TEVA SOLUTION FOR INJECTION 100MG/ML

February 26, 2024

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

INTRAVENOUS

Medical Information

V03AB35

sugammadex

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

PLIVA Croatia Ltd.

Active Ingredients

Sugammadex Sodium eqv. to Sugammadex

100mg/ml

Sugammadex

Documents

Package Inserts

Sugammadex Teva Solution for Injection PI.pdf

Approved: February 26, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.